Publisher
Springer Science and Business Media LLC
Reference26 articles.
1. Ceraso A, Lin JJ, Schneider-Thoma J, Siafis S, Tardy M, Komossa K, Heres S, Kissling W, Davis JM, Leucht S (2020) Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev 8:CD008016. https://doi.org/10.1002/14651858.CD008016.pub3
2. Chan SKW, Suen YN, Yan WC, Lam C, Chui E, Hui CLM, Chang WC, Lee EHM, Chen EYH, Honer WG, Takeuchi H (2023) Clozapine dosing patterns and clinical outcomes in patients with treatment resistant schizophrenia. Eur Neuropsychopharmacol 75:67–79. https://doi.org/10.1016/j.euroneuro.2023.07.007
3. FDA (2020) CLOZARIL® Prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/019758s095lbl.pdf. Accessed 19 Jun 2024
4. García S, Martínez-Cengotitabengoa M, López-Zurbano S, Zorrilla I, López P, Vieta E, González-Pinto A (2016) Adherence to antipsychotic medication in bipolar disorder and schizophrenic patients: a systematic review. J Clin Psychopharmacol 36:355–371. https://doi.org/10.1097/JCP.0000000000000523
5. Guy W (1976) ECDEU assessment manual for psychopharmacology. U.S. Department of health, education, and welfare, public health service, alcohol, drug abuse, and mental health administration, national institute of mental health, psychopharmacology research branch, division of extramural research programs, pp 218–222